Early-Phase Clinical Development
Senior clinical operations expertise for biotech companies entering human trials. Hands-on support from strategy to execution, without the full-time cost.
What we do
NeoAlchemy Clinical supports biotech companies entering or navigating early clinical development where decisions are high-risk, capital is limited, and where structure and leadership are essential, but must remain tailored and proportional.
From strategy to execution, we help biotech teams transform scientific potential into structured, credible clinical programs that generate tangible company value.
Our core focus is early clinical development: from preclinical transition to Phase I & Proof of Concept where key value inflection points are defined.
We also support growing biotech companies that are beyond the early phase but not yet structured like large pharma. Organizations that need to:
Whether you are launching your first trial or restructuring for performance, our approach remains the same: turn your vision into measurable progress with support tailored to your stage, resources, and ambitions.
Who we work with
We work primarily with early-stage biotech companies transitioning from preclinical to clinical development, when strategic clarity and operational rigor are critical to success.
Our clients are looking for clarity, efficiency, and real progress.
They understand that early clinical development is more than running a clinical trial.
It is about building long-term company value.
They need the right expertise to support value creation and turn ambition into execution.
They trusted us
She anticipates, reassures and finds solutions, even in the most demanding situations. You immediately feel confident working with her.
Virginie is definitively the best to answer questions or doubts in clinical trial field. Her knowledge does not have an end. She's got the power to elevate a team.
Virginie was the true cornerstone of the clinical, logistical, and operational teams. Her ability to harmonize efforts was essential to the achievement of our objectives.
FAQ
No. NeoAlchemy is not a CRO.
We do not replace operational vendors. We work alongside them and with you.
NeoAlchemy integrates into your team to provide strategic oversight, structure, and leadership.
You keep the flexibility of working with a consultant, while benefiting from the level of involvement and ownership of an internal leader.
It is the best of both worlds: Flexibility, Senior expertise and Strategic alignment.
Hiring is a major strategic step. Many biotech companies are not yet sure which profile they truly need, or whether they can sustain a full-time leadership position.
Working with NeoAlchemy allows you to:
Once the structure is mature, hiring becomes clearer and safer.
Yes. NeoAlchemy often works alongside existing CROs to:
A CRO executes. You still need internal strategic ownership.
Early clinical development is our core focus.
However, we also support growing biotech companies that need to restructure, strengthen governance, or improve performance without adopting heavy big-pharma infrastructure.
As early as possible. Ideally, 1 to 2 years before your expected First Patient In (FPI).
Early preparation allows you to:
The earlier we structure your strategy, the smoother your execution will be.
We start with a free introductory call to understand your situation and clarify what you will need and when.
You can also follow our founder on LinkedIn, where she regularly shares practical insights and free resources on early-phase clinical development.
NeoAlchemy supports innovative drug development programs, including small molecules, biologics, and advanced therapies such as cell and gene therapies.
The focus is primarily on early clinical development, particularly for complex or high-risk programs where structure, strategic clarity, and strong execution are critical.
Regardless of the modality, the objective remains the same: structure development efficiently and turn clinical progress into company value.
Every collaboration is tailored to your stage, scope, and level of involvement.
Senior expertise has a cost, but the fractional and flexible model allows you to access high-level clinical leadership without the fixed cost of a full-time executive.
The objective is to create value, protect capital, and prevent costly mistakes.
Engagements are structured to fit your needs and your budget whether for a focused strategic discussion or a longer-term partnership.
We discuss scope and investment transparently during our initial conversation.
Let's start with a conversation.
Early clinical decisions shape long-term value. Let's make them count.